Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1641-1646

  Bhagirath, Divya ^a   Abrol, Nitin ^a   Khan, Rehan ^a   Sharma, Manoj ^b   Seth, Amlesh ^a   Sharma, Alpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

BIGH3; Bladder cancer; CD147; Diagnostic marker; Stathmin

Indexed keywords

CD147 ANTIGEN; GROWTH FACTOR BETA INDUCIBLE PROTEIN; MESSENGER RNA; STATHMIN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER STAGING; CD147 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GROWTH FACTOR BETA INDUCIBLE PROTEIN GENE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; STATHMIN GENE; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ANTIGENS, CD147; CARCINOMA, TRANSITIONAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATHMIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84864393097     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.05.005     Document Type: Article

References (31)

1. Sharma S., Ksheersagar P., Sharma P. Diagnosis and treatment of bladder cancer. Am Fam Physician 2009, 80(7):717-723.
2. Van Tilborg A.A., Bangma C.H., Zwarthoff E.C. Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 2009, 16(1):23-30.
3. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009, 22:S53-S59.
4. Bassi P., De Marco V., De Lisa A., et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005, 75(3):193-200.
5. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005, 66:35-63.
6. Zhang W., Erkan M., Abiatari I., et al. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol Ther 2007, 6(2):218-227.
7. Voight H., Claudia S., Kauczok V., et al. CD147 impacts angiogenesis and metastasis formation. Cancer Invest 2009, 27:329-333.
8. Tang Y., Nakada M.T., Kesavan P., et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinase. Cancer Res 2005, 65:3193-3199.
9. Tang Y., Kesavan P., Nakada M.T., Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2004, 2(2):73-80.
10. Billings P.C., Herrick D.J., Kucich U., et al. Extracellular matrix and nuclear localisation of BIGH3 in human bladder and fibroblast cells. J Cell Biochem 2000, 79:261-273.
11. Billings P.C., Whitbeck J.C., Adams C.S., et al. Transforming growth factor-beta induciblematrix protein Bigh3 interacts with fibronectin. J Biol Chem 2002, 277:28003-28009.
12. Tang J., Zhou H.W., Jiang J.L., et al. Bigh3 is involved in HAb/CD147 mediated metastasis process in Human Hepatoma cells. Exp Biol Med 2007, 232:344-352.
13. Rubin C.L., Atweh G.F. Role of stathmin in regulation of cell cycle. J Biol Chem 2004, 93:242-250.
14. Luo X.-N., Mookerjee B., Ferrari A., Mistry S., Atweh G.F. Regulation of phosphoprotein p18 in leukemic cells. J Biol Chem 1994, 269:10312-10318.
15. Bieche I., Lachkar S., Becette V., et al. Overexpression of the Stathmin gene in a subset of human breast cancer. Br J Cancer 1998, 78:701-709.
16. Wei S.H., Lin F., Wang X., et al. Prognostic significance of Stathmin expression in correlation with metastasis and clinicopathological characterstics in human ovarian carcinoma. Acta Histochem 2008, 110:59-65.
17. Jeon T.Y., Han M.E., Lee Y.W., et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer Feb 16 2010, 102(4):710-718.
18. Lin W.C., Chen S.C., Chueh S.C., et al. Expression of stathmin in localised upper urinary tract urothelial carcinoma: correlation with prognosis. Urology 2009, 74:1264-1270.
19. Hanash S.M., Strahler J.R., Kuik R., Chu E.H.Y., Nichols D. Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 1988, 263:12813-12815.
20. Zhang H.Z., Wang Y., Gao P., et al. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther 2006, 5(11):1457-1461.
21. Alli E., Yang J.M., Hait W.N. Silencing of Stathmin induces tumor suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007, 26(7):1003-1012.
22. Guirguis R., Javadpour N., Sharareh S., et al. A new method for evaluation of urinary autocrine motility factor and tumor cell collagenase stimulating factor as markers for urinary tract cancers. J Occup Med 1990, 32(9):846-853.
23. Javadpour N., Guirguis R. Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer-an update. Eur Urol 1992, 21:1-4.
24. Cheng L., Montironi R., Davidson D.D., Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009, 22(Suppl. 2):S70-S95.
25. Schmittgen T.D., Livak K.J. Analysing real-time PCR data by comparative C(T) method. Nat Protoc 2008, 3(6):1101-1108.
26. Satyam A., Singh P., Sharma M., Seth A., Sharma A. CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder. Biomarkers 2011, 16(5):413-421.
27. Ma C., Rong Y., Radiloff D.R., et al. Extracellular matrix protein beta ig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008, 22(3):308-321.
28. Sasaki H., Kobayashi Y., Nakashima Y., et al. Beta-IGH3, a TGF-beta inducible gene, is overexpressed in lung cancer. Jpn J Clin Oncol 2002, 32(3):85-89.
29. Schneider D., Kleeff J., Berberat P.O., et al. Induction of Bigh3 in pancreatic cancer cells. Biochem Biophys Acta 2002, 1588:1-6.
30. Calaf G.M., Echiburu-Chau C., Zhao Y.L., Hei T.K. Bigh3 protein expression as a marker for Breast cancer. Int J Mol Med 2008, 21:561-568.
31. Yamanaka M., Kimura F., Kagata Y., et al. BIGH3 is overexpressed in Clear cell Renal Carcinoma. Oncol Rep 2008, 19:865-874.